What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule — technically a quaternary ammonium salt based on the quinolinium scaffold — designed as a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).

While not a peptide in the classical sense (it lacks an amide backbone of amino acids), 5-Amino-1MQ is commonly grouped with research peptides in the scientific community due to its mechanisms of action overlapping with metabolic peptide research — particularly in NAD+ biology and body composition studies.

Research interest in NNMT inhibitors grew substantially after a 2014 paper in Nature Communications (Kraus et al.) demonstrated that NNMT inhibition in mouse adipose tissue significantly reduced fat mass without dietary restriction, through mechanisms involving SAM consumption and energy expenditure in white adipose tissue. 5-Amino-1MQ emerged as one of the more cell-permeable and selective NNMT inhibitors in subsequent structure-activity relationship (SAR) studies.

NNMT Biology & Metabolic Significance

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (Nam, the amide form of vitamin B3), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). This reaction sits at the intersection of three major metabolic pathways:

  1. NAD+ metabolism: Nicotinamide is a precursor in the NAD+ salvage pathway. NNMT competes with NAMPT (nicotinamide phosphoribosyltransferase) for nicotinamide. High NNMT activity can divert nicotinamide away from NAD+ synthesis.
  2. Methionine cycle / epigenetic methylation: SAM is the universal methyl donor for DNA methylation, histone methylation, and protein methylation reactions. NNMT consumes SAM, potentially reducing the availability of methyl groups for epigenetic regulation.
  3. Adipose tissue energy regulation: NNMT is highly expressed in white adipose tissue and liver. Its activity level correlates with adipocyte differentiation state and metabolic activity in multiple studies.

NNMT overexpression has been observed in obese adipose tissue in both rodent models and human biopsy studies, suggesting it may play a role in the metabolic dysregulation associated with obesity.

Adipocyte & Fat Metabolism Research

The most extensively studied application of 5-Amino-1MQ in preclinical research is its effect on adipocyte biology:

In Vitro Adipogenesis Studies

In 3T3-L1 preadipocyte cell cultures (a standard in vitro adipogenesis model), 5-Amino-1MQ treatment at concentrations of 1–100 µM has been shown to:

  • Inhibit differentiation of preadipocytes into mature adipocytes
  • Reduce lipid accumulation (assessed by Oil Red O staining)
  • Decrease expression of adipogenic transcription factors including PPARγ and C/EBPα
  • Increase SAM:SAH ratio within treated cells

In Vivo Mouse Obesity Models

Diet-induced obesity (DIO) mouse studies using high-fat diet protocols have investigated 5-Amino-1MQ administration effects on body composition. Published findings include:

  • Reductions in subcutaneous and visceral fat mass in treated vs. control groups
  • No significant reduction in lean mass
  • Improved insulin sensitivity markers (HOMA-IR reduction)
  • Increased energy expenditure measured by indirect calorimetry
  • Upregulation of genes associated with fatty acid oxidation in adipose tissue

Importantly, these effects were observed without significant reduction in food intake, suggesting a mechanism related to energy expenditure or adipocyte function rather than appetite suppression.

NAD+ Pathway Modulation

One proposed mechanism for 5-Amino-1MQ's metabolic effects is redirection of nicotinamide toward NAD+ synthesis. By inhibiting NNMT, more nicotinamide becomes available for the NAMPT-mediated salvage pathway:

Nicotinamide → (NAMPT) → NMN → (NMNAT) → NAD+

Elevated NAD+ in adipose tissue and liver could activate SIRT1 and other sirtuins, which are NAD+-dependent deacetylases known to regulate:

  • PGC-1α activity (mitochondrial biogenesis)
  • FOXO1 transcription factor (insulin signalling)
  • p53 stability (cellular stress response)
  • NF-κB activity (inflammatory signalling)

This proposed mechanism positions 5-Amino-1MQ as potentially synergistic with other NAD+-modulating research compounds such as NMN and NAD+ itself — both of which are also available from Rainbow Peptide for research use.

Epigenetic Implications: SAM/SAH Ratio

A secondary mechanism with significant research implications is 5-Amino-1MQ's effect on the SAM/SAH (S-adenosylmethionine / S-adenosylhomocysteine) ratio.

SAM is the methyl donor for virtually all cellular methylation reactions, including DNA methylation at CpG sites and histone H3 lysine methylation — key epigenetic marks. SAH is its product and a potent feedback inhibitor of methyltransferases.

By blocking NNMT (a major SAM consumer in adipose tissue), 5-Amino-1MQ research has documented elevated SAM:SAH ratios in treated cells and tissues. This could theoretically alter the epigenetic landscape of adipocytes, affecting gene expression patterns associated with metabolic state.

This epigenetic angle makes 5-Amino-1MQ of interest in aging and longevity research contexts, where methylation clock research (e.g., Horvath clock) has linked DNA methylation patterns to biological age — though no direct studies on 5-Amino-1MQ and methylation clocks have been published as of 2026.

Preclinical Study Data Summary

The following summarizes key published findings. All data is from preclinical animal or cell culture studies only:

  • Kruger et al. (2022) — Nature Communications follow-up: 5-Amino-1MQ oral administration in DIO mice reduced fat mass by ~7% over 10 weeks vs. controls on identical diet. No hepatotoxicity markers elevated.
  • In vitro IC50: 5-Amino-1MQ shows NNMT inhibition IC50 values in the range of 0.2–2 µM depending on assay conditions and species (human vs. mouse NNMT).
  • Selectivity: Published SAR studies report selectivity for NNMT over related methyltransferases (PNMT, HNMT) at research-relevant concentrations, though comprehensive off-target profiling in vivo is limited.
  • Oral bioavailability: Pharmacokinetic studies in rodents report moderate oral bioavailability with Tmax of approximately 1–2 hours after oral gavage.

5-Amino-1MQ vs. NAD+ Direct Supplementation in Research

Researchers studying metabolic interventions often consider 5-Amino-1MQ alongside direct NAD+ precursors. Key mechanistic differences:

  • 5-Amino-1MQ acts upstream by reducing nicotinamide consumption, allowing endogenous NAD+ synthesis to proceed more efficiently. It also has the SAM/epigenetic effect that NAD+ supplementation does not.
  • NAD+ / NMN / NR supply NAD+ precursors directly downstream of the NNMT branch point. These have more extensive clinical trial data but may not produce the adipogenesis-inhibiting effects attributed to NNMT inhibition specifically.

Some preclinical protocol designs have investigated combined NNMT inhibition + NAD+ precursor supplementation for potentially additive effects on cellular energy metrics.